Zobrazeno 1 - 10
of 486
pro vyhledávání: '"RET fusion"'
Autor:
An Wang, Tao Li, Yun-ye Mao, Ming Gao, Sheng Shu, Chang-hong Xia, Yi Dong, Min Liu, Jin-liang Wang, Jun-xun Ma, Yi Hu
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Objective The present study endeavors to furnish an exhaustive review of the research advancements on solid tumors harboring RET rearrangement within the Chinese context, particularly emphasizing the examination of real-world therapeutic str
Externí odkaz:
https://doaj.org/article/14da8b0790fc4a759a33afbba168afbc
Publikováno v:
Journal of Cardiothoracic Surgery, Vol 19, Iss 1, Pp 1-6 (2024)
Abstract This case report details the successful treatment of a 68-year-old male patient with locally advanced RET-rearranged lung adenocarcinoma using neoadjuvant pralsetinib. The patient initially presented with a suspicious right upper lobe nodule
Externí odkaz:
https://doaj.org/article/637b3f31a86245ada09565dd2f0bd1b7
Autor:
Hiroki Ohkoshi, Masafumi Saiki, Nozomu Takahashi, Kenta Homma, Satoshi Furuya, So Shimamura, Chisa Omori, Yuki Hoshino, Yoshinori Uchida, Shinnosuke Ikemura, Kenzo Soejima
Publikováno v:
Thoracic Cancer, Vol 15, Iss 25, Pp 1863-1866 (2024)
Abstract Selpercatinib is the first targeted therapy for rearranged during transfection (RET) fusion‐positive unresectable non‐small‐cell lung cancer (NSCLC). The main adverse effects of selpercatinib include hypertension, liver dysfunction, di
Externí odkaz:
https://doaj.org/article/716797d0b1244a2fadca993c1d2f1f18
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 12, Pp 100730- (2024)
RET fusion-positive NSCLC accounts for 1% to 2% of lung carcinoma cases. Although two Food and Drug Administration–approved selective RET inhibitors, pralsetinib, and selpercatinib, have revealed efficacy in managing RET fusion-positive NSCLC, this
Externí odkaz:
https://doaj.org/article/b85dc2fa0d424aee88a8beffee93b8fd
Autor:
Hejing Bao, Jiani Zhang, Yuhuan Wang, Zhiting Chen, Xi Luo, Ting Li, Haoran Su, Hehong Bao, Xiaolong Cao, Liping Lin
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
We report a case of an advanced non-small cell lung cancer (NSCLC) patient with brain metastasis, RET fusion, and high expression of programmed death ligand 1 (PD-L1) at initial treatment. After receiving radiotherapy for the brain metastasis, the pa
Externí odkaz:
https://doaj.org/article/220e0729461b489eab3a0b8454876372
Autor:
Jacobi B. Hines, MD, Benjamin C. Bowar, PharmD, Margaret Colleton, MMS, Lydia Chelala, MD, Peng Wang, MD, Angad A. Chadha, MD, Jeremy Segal, MD, Christine M. Bestvina, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100724- (2024)
RET fusions are present in 1% to 2% of NSCLCs. Although RET inhibitors like selpercatinib are effective, resistance inevitably develops. We present the case of a 28-year-old female with recurrent NSCLC and a CCDC6::RET fusion treated with selpercatin
Externí odkaz:
https://doaj.org/article/dc5a5a8ec8b44c4a9204b2a1fb65c01b
Publikováno v:
Current Oncology, Vol 31, Iss 7, Pp 3808-3814 (2024)
The application of adjuvant treatment has significantly enhanced the survival of patients with resectable non-small cell lung cancer (NSCLC) carrying driver gene mutations. However, adjuvant-targeted therapy remains controversial for some NSCLC patie
Externí odkaz:
https://doaj.org/article/12fd65a45b334748b4b06db515420ffa
Publikováno v:
Lung Cancer: Targets and Therapy, Vol Volume 15, Pp 75-80 (2024)
Alexandria TM Lee,1 Sai-Hong Ignatius Ou2 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, 92868, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USACorrespondence: Sai-Hong Ignatius Ou, Depar
Externí odkaz:
https://doaj.org/article/239290dacf054e06a8a3547851c8fc4e
Publikováno v:
Heliyon, Vol 10, Iss 14, Pp e34626- (2024)
Background: The Rearranged during Transfection (RET) gene represents a rare driver mutation in non-small cell lung cancer (NSCLC) occurring in only 1 %–2 % of cases, with implications in targeted carcinogenesis. Despite the significant efficacy dem
Externí odkaz:
https://doaj.org/article/26a064d2e52c4ab5a82687cba5ee1037
Autor:
Rafal Dziadziuszko, Nir Peled, Tony Mok, Solange Peters, Santiago Ponce Aix, Jorge Alatorre-Alexander, Brian D. Vicuna, Margaret Maclennan, Vijay Bhagawati-Prasad, Sarah M. Shagan, Erica Schleifman, Thorsten Ruf, Michael S. Mathisen, Shirish M. Gadgeel
Publikováno v:
Contemporary Oncology, Vol 27, Iss 4, Pp 217-223 (2024)
Externí odkaz:
https://doaj.org/article/de66fd03358a49bbbdeaeff487884027